Entropy Neurodynamics Limited (ASX: ENP) - Share Price
Current share price for ENP : $0.032 0.001 (3.23%)+
Entropy Neurodynamics Limited (ENP, formerly Tryptamine Therapeutics Limited), an ASX-listed company,, is a clinical-stage biotechnology company focused on developing patented, original formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs.
ENP General Information +
| ASX Code | ENP |
| Website | http://www.tryptherapeutics.com |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 52 |
| ENP Share Price | $0.032 |
| Day High | $0.032 |
| Day Low | $0.031 |
| Last Close | $0.031 |
| ENP Share Price Movement | $0.00 ( 3.23% ) |
Prices as at 16:40, 26 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Entropy Neurodynamics Limited (ENP) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Entropy Neurodynamics Limited (ENP) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Entropy Neurodynamics Limited (ENP) price-sensitive announcements
ENP - DSMB Clears TRP 8803 to Advance to Cohort 2
Entropy Neurodynamics Limited announced the progression of its TRP-8803 program for Binge
Entropy Neurodynamics Limited (ENP)
15 Jun 2026 | 9:55 AM
15 Jun 2026 | 9:55 AM
ENP - Entropy completes Cohort 1 dosing in BED trial
Entropy Neurodynamics Limited has successfully completed the dosing of the first cohort in
Entropy Neurodynamics Limited (ENP)
2 Jun 2026 | 8:56 AM
2 Jun 2026 | 8:56 AM
ENP - Entropy files new US patent for IBS program
Entropy Neurodynamics Limited, a clinical-stage biotechnology company, has filed a new US
Entropy Neurodynamics Limited (ENP)
5 May 2026 | 9:38 AM
5 May 2026 | 9:38 AM
ENP - TRP 8802 delivers 75% breakthrough response in IBS
Entropy Neurodynamics Limited announced a breakthrough in its Phase 2a clinical trial of T
Entropy Neurodynamics Limited (ENP)
4 May 2026 | 9:08 AM
4 May 2026 | 9:08 AM
Entropy Neurodynamics Limited (ENP) Recent ASX Announcements
ENP Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$5.19 | -$0.40 | -56.30% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$4.39 | -$0.90 | -76.00% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$7.13 | -$3.60 | -43.60% | 0.00 | 0.00 | 0.00% | 0.0% |
ENP Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $761M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Entropy Neurodynamics Limited (ENP) | $51M | -0.5632 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $1,618M | -0.7857 | 0.0743 | 1.2000 | 54.8346 | 51.0400 | 23.2000 | 0.00% | 0.00% | 0.00% |
ENP Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 7.80 | 0.00 |
| Market | 0.29 | 13.30 | 1.15 | 0.66 |
| Sector | 0.42 | 26.20 | 2.41 | 2.34 |
ENP Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Ian Edward Dixon | Chief Executive Officer | 15 May 2013 |
| Mr Christopher Ntoumenopoulos | Executive Director | 1 May 2024 |
| Mr Herwig Janssen | Non-Executive Chairman, Non-Executive Director | 12 May 2025 |
| Dr Daniel Tillett | Non-Executive Director | 8 Nov 2024 |
| Mr Jason Alan Carroll | Non-Executive Director | 1 May 2024 |
| Mr Gage Jull | Non-Executive Director | 1 May 2024 |
Entropy Neurodynamics Limited (ENP) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 13 May 2026 | CARROLL, Jason | Buy | Direct Shares | 538,236 | $0.036 | $19,376.000 |
| 12 May 2026 | CARROLL, Jason | Buy | Direct Shares | 750,000 | $0.035 | $26,250.000 |
| 17 Apr 2026 | JANSSEN, Herwig | Issued | Direct Shares | 726,195 | $0.034 | $25,000.000 |
See all changes in directors' interest & trades for Entropy Neurodynamics Limited (ENP) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
ENP Management
| Name | Position |
|---|---|
| Hamish George | Company Secretary |
| Jim Gilligan | President and Chief Scientific Officer |
ENP Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Entropy Neurodynamics Limited (ENP). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 157,900,000 (11.36%) | William Garner |
| 92,315,409 (6.64%) | Citicorp Nominees Pty Limited |
ENP Calendar of Events
| Date | Event |
|---|---|
| 26 February 2027 | Report (Interim) |
| 28 August 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
